National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Search
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Osteosarcoma/Malignant Fibrous Histiocytoma of Bone Treatment (PDQ®)
Patient VersionHealth Professional VersionEn españolLast Modified: 04/02/2008



Purpose of This PDQ Summary






General Information






Prognostic Factors






Cellular Classification






Staging and Site Information






Treatment Option Overview






Localized Osteosarcoma/Malignant Fibrous Histiocytoma of Bone






Metastatic Disease at Diagnosis






Recurrent Osteosarcoma






Get More Information From NCI







Changes to This Summary (04/02/2008)






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

NIH Calendar of Events

Español
NCI Highlights
New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

President's Cancer Panel Annual Report: 2006-2007

Cancer Trends Progress Report: 2007 Update

Past Highlights
HPV Vaccines for Cervical Cancer
Changes to This Summary (04/02/2008)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Prognostic Factors

Added Fernandes et al. as reference 5.

Added text to state that not every nodule detected indicates metastatic disease.

Added text to state that patients with less necrosis (<90%) in the primary tumor following initial chemotherapy have a higher rate of recurrence within the first 2 years (cited Kim et al. as reference 25).

Added Heinsohn et al. as reference 43.

Added text to state that malignant fibrous histiocytoma of bone is seen more commonly in older adults.

Staging and Site Information

Added text about the Enneking staging system for musculoskeletal neoplasms and the basis for the system (Enneking et al. as reference 1).

Localized Osteosarcoma/Malignant Fibrous Histiocytoma of Bone

Added text to state that in a large Cooperative Osteosarcoma Study Group trial, higher chemotherapy dose intensity did not correlate with improved outcome (cited Eselgrim et al. as reference 18).

Metastatic Disease at Diagnosis

Added text to state that high dose ifosfamide in combination with etoposide produced a complete or partial response in patients with newly diagnosed metastatic osteosarcoma (cited Goorin et al. as reference 7).

Recurrent Osteosarcoma

Added text to state that the incidence of local relapse was higher in patients who had a poor pathologic response to chemotherapy in the primary tumor and in patients with inadequate surgical margins (cited Bacci et al. as reference 23).

Added Berrak et al. as reference 29.

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov